I’m surprised no one has caught on to Acadia’s retail naming of “daybue” (debut), the world’s introduction to the first neurodevelopment disorder treatment drug, Neuren’s first platform for Retts syndrome and then comes the others, ultimately hopefully Autism spectrum, all neurodevelopment disorders, this is why I believe that they should leave TBI alone till a lot further on simply because it’s an acquired brain injury.
Just an opinion.
Acadia, page-169
-
- There are more pages in this discussion • 509 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.13 |
Change
0.020(0.15%) |
Mkt cap ! $1.678B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.44 | $13.07 | $5.021M | 378.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 11501 | $13.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.18 | 1539 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |